Grace Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
GRCE$1.87+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| June 30, 2026 | March 31, 2026 | |
|---|---|---|
| (Expressed in thousands except share data) | $ | $ |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | 13,756 | 16,977 |
| Receivables | 20 | 20 |
| Prepaid expenses | 557 | 383 |
| Total current assets | 14,333 | 17,380 |
| Equipment, net | 7 | 8 |
| Intangible assets | 27,595 | 41,128 |
| Goodwill | 8,138 | 8,138 |
| Total assets | 50,073 | 66,654 |
| Liabilities and Stockholders’ equity | ||
| Current liabilities: | ||
| Trade and other payables | 1,250 | 2,146 |
| Total current liabilities | 1,250 | 2,146 |
| Deferred tax liability | 612 | 612 |
| Total liabilities | 1,862 | 2,758 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value per share; 10,000,000 authorized; none issued and outstanding as of June 30, 2026 and March 31, 2026 | — | — |
| Common stock, $0.0001 par value per share; 100,000,000 authorized; 16,274,026 and 16,024,026 shares issued and outstanding as of June 30, 2026 and March 31, 2026, respectively | 1 | 1 |
| Additional paid-in capital | 298,518 | 298,413 |
| Accumulated other comprehensive loss | (6,038) | (6,038) |
| Accumulated deficit | (244,270) | (228,480) |
| Total stockholders' equity | 48,211 | 63,896 |
| Total liabilities and stockholders’ equity | 50,073 | 66,654 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.